President of Baqiyatallah University says:

Tehran (IP) – President of Baqiyatallah University of Medical Sciences says the Iranian-made 'Noora' coronavirus vaccine complies with all Iran Food and Drug Administration (FDA) standards.

Iran PressIran news: In an exclusive interview with Iran Press on the characteristics of an Iranian indigenized 'Noora' coronavirus vaccine, Hassan Abolghasemi noted that the recombinant vaccine entered the human trial stage, and it was hoped to get the FDA's approval to be used for nationwide vaccination.

Speaking on the sidelines of the opening ceremony of Integrated Drive-In COVID-19 Vaccination Base on Tuesday, Abolghasemi said: "In the first phase 70 people were vaccinated and we hope to start the 2nd and 3rd phases simultaneously."

Under normal conditions, Noora recombinant vaccine would take another four or five months to get ready for nationwide vaccination. However, suppose it got an FDA license due to the urgent needs. In that case, it might enter the vaccination cycle within the next two months, Baqiyatallah University of Medical Sciences' President Hassan Abolghasemi pointed out. 

The opening ceremony of Integrated and Drive-In COVID-19 Vaccination Base was held at the Tehran Int'l Exhibition Permanent Fairground in cooperation with Baqiyatallah University of Medical Sciences.

The ceremony was attended by Alireza Zali, the President of Shahid Beheshti University of Medical Sciences, Hassan Abolghasemi, the President of Baqiyatallah University of Medical Sciences, and other health officials Tuesday, July 27.


Read More: 

Clinical trial of Noora corona vaccine successfully completed

COV-Iran Barakat vaccine, game changer in immunizing Iranian society